TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02713893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Econazole nitrate 1% intravaginal cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus Benzydamine HCl 0.12% intravaginal cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravaginal cream
Study: NCT02929394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Description: Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity
Study: NCT04306276

Intervention type: DRUG
Intervention: Dienogest 2 MG
Description: Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF
Study: NCT02194335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS - in single rising doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02851277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0892 Intradermal
Description: Intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0892 Intradermal
Description: Intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0892 Intramuscular
Description: Intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intradermal
Description: Intradermal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intramuscular
Description: Intramuscular injection
Study: NCT03499483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bictegravir
Description: Single One Pill Formulation of bictegravir, emtricitabine/tenofovir alafenamide (Bictarvy) to be taken once daily orally for a period of 28 days.
Study: NCT02479399

Intervention type: DRUG
Intervention: ipragliflozin
Description: Tablets
Study: NCT04560400

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Conventional King-Devick test
Description: Conventional King-Devick test involves a series of number reading task from left to right and top to bottom, intending to test subjects' neuro-ophthalmologic function

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Conventional King-Devick test
Description: Conventional King-Devick test involves a series of number reading task from left to right and top to bottom, intending to test subjects' neuro-ophthalmologic function

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Conventional King-Devick test
Description: Conventional King-Devick test involves a series of number reading task from left to right and top to bottom, intending to test subjects' neuro-ophthalmologic function

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reverse King-Devick test
Description: Reverse King-Devick test involves a series of number reading task from right to left and bottom to top, intending to test subjects' neuro-ophthalmologic function

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reverse King-Devick test
Description: Reverse King-Devick test involves a series of number reading task from right to left and bottom to top, intending to test subjects' neuro-ophthalmologic function

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reverse King-Devick test
Description: Reverse King-Devick test involves a series of number reading task from right to left and bottom to top, intending to test subjects' neuro-ophthalmologic function
Study: NCT03343912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.400 mg/day and Trimegestone 0.06 mg/day
Description: Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.300 mg/day and Trimegestone 0.12 mg/day
Description: Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.200 mg/day and Trimegestone 0.18 mg/day
Description: Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application
Study: NCT03956849

Intervention type: OTHER
Intervention: Training COACH Conversationstarter
Description: After elaborating perceived barriers and facilitators via surveys and semi-structured focusgroups, a short training with the COACH Conversationstarter will be provided to a part of the participants. The COACH Conversationstarter will be provided to the participants attending the training, which they can use in the next couple of months. After a period of time all participants will be provided with a second questionnaire, and results of the group that received the COACH Conversationstarter will be compared with the group that didn't receive the COACH Conversationstarter. (A part of) the participants that used the COACH Conversationstarter will be interviewed about their experiences.~However, the study will have an observational design, since the decision if a professional is attending the training is not based on the investigator / protocol, but depending on the professional, for example logistic reasons. This is part of routine education.
Study: NCT02946138

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon-ion radiotherapy
Description: Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions
Study: NCT04730700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation with MEE
Description: RFA will be performed in the usual fashion utilizing the MEE instead of the RFA needles routinely used at each institution.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management
Description: Conventional medical management (CMM), which may include physical therapy, home exercise programs, pain medication, and other conservative therapies such as back brace, walking aid, and chiropractic care.
Study: NCT03829540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4CAR
Description: CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
Study: NCT02923726

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1 (ATP+Shock)
Description: Subjects will be randomized and device programmed to the respective arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 2 (shock only)
Description: Subjects will be randomized and device programmed to the respective arm.
Study: NCT01300754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose Injection
Description: 12.5 Dextrose in 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Injection
Description: 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Therapist supervised exercises that are standard of care for Osgood-Schatter Disease as well as relative rest and gradual resumption of pain-limited sport.
Study: NCT04442295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-001 - Single Ascending Doses
Description: Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-001 - Multiple Ascending Doses
Description: Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).
Study: NCT01122238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks.
Study: NCT01170559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder
Study: NCT02437071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
Study: NCT02731586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic Mesenchymal stem cells
Description: Allogenic mesenchymal stem cells are introduced during placement of dental implants.
Study: NCT03802006

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound assessment of gastric content
Description: Ultrasound assessment of gastric body is performed
Study: NCT04475978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS-guide DCB PTCA
Description: IVUS-guide DCB PTCA

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Angio-guide DCB PTCA
Description: Angio-guide DCB PTCA
Study: NCT03480581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forward First ICARE Training
Description: Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reverse First ICARE Training
Description: Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
Study: NCT03331315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Study: NCT02437071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Study: NCT00682890

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo birth control pill daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 2000 mg per day for 3 months daily birth control pill
Study: NCT01323647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PoliorixTM
Description: Single dose, intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix+Hib
Description: Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix+Hib
Description: Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
Study: NCT01426867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide ophthalmic suspension, 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution, 0.2%
Study: NCT01948726

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation with simultaneous integrated boost
Study: NCT02199704

Intervention type: OTHER
Group type: OTHER
Intervention: Self Directed Positive Parenting Program
Description: Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders \& Turner, 1999) and up to ten sessions of support. This is a case series study.
Study: NCT02923687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the experimental group will receive supplemental buccal infiltration of 30 mg/mL of Ketorolac Tromethamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, control group will receive buccal infiltration of normal saline.
Study: NCT01358487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-help course plus live follow-up if needed
Description: In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online + incentives Follow-up Group
Description: This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
Study: NCT03536754

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo tablets, taken twice daily (BID), per os, for 84 days (12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: One 5 mg CCX140-B tablet and 2 placebo tablets in the morning; 3 placebo tablets in the evening; per os, for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: Two 5 mg CCX140-B tablets and 1 placebo tablet, taken BID; per os, for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: Three 5 mg CCX140-B tablets, taken BID; per os, for 84 days.
Study: NCT02317133

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.

Intervention type: BIOLOGICAL
Intervention: Stool samples
Description: Stool samples will be collected for the observational needs of this study (and are not part of routine practice).

Intervention type: BIOLOGICAL
Intervention: Stool samples
Description: Stool samples will be collected for the observational needs of this study (and are not part of routine practice).

Intervention type: BIOLOGICAL
Intervention: Stool samples
Description: Stool samples will be collected for the observational needs of this study (and are not part of routine practice).
Study: NCT02801968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tap block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous analgesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesia
Study: NCT00252577

Intervention type: DRUG
Intervention: Lithium treatment
Description: Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
Study: NCT03099746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVOLVE
Description: Interactive content and decision coaching with tailored framing of messages to subject's informational processing style and stage of change to promote participatory decision making behavior. Consideration of options, consequences, values, and preferences to formulate an informed decision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Support
Description: Passive, non-tailored informational support. Screen-based education (videos) with information content on advance care decisions that occur in the intensive care unit.
Study: NCT03149679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy
Study: NCT03817359

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol mixture
Description: Participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump in intervention group. All TCI target concentration adjustments or extra bolus of propofol or remifentanil during operation were based on BIS and ANI monitor.
Study: NCT03099746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Routine decision support practices by the healthcare team. Family meetings, bedside updates, and access to printed or electronic decision aids.
Study: NCT03099499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
Study: NCT02031692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
Description: The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
Study: NCT04312217

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical clowning
Description: Medical clowning
Study: NCT01759576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
Study: NCT04206930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: 1 session of 2 hours per week in a closed group for 10 weeks